1514 - Updated Results From the Phase 1 Study of Sonrotoclax (BGB-11417), a Novel B-Cell Lymphoma 2 Inhibitor, in Combination With Zanubrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Demonstrate Deep and Durable Responses

Primary Author / Presenter(s)

SO

Stephen Opat, MD, FRACP, FRCPA, MBBS

Lymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University
Clayton, Australia

Co-Author(s)

CT

Constantine S. Tam, MD, MBBS

Consultant Haematologist
Alfred Hospital and Monash University
Melbourne, Victoria, Australia
Mary Ann Anderson, MBBS, FRACP, FRCPA, PHD

Consultant Haematologist
Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia;Division of Blood Cells and Blood Cancer, Walter and Eliza Hall Institute;Department of Medical Biology, The University of Melbourne
Melbourne, Victoria, Australia
AT

Alessandra Tedeschi, MD

ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
EV

Emma Verner, MBBS, BMedSci, FRACP, FRCPA

Concord Repatriation General Hospital; University of Sydney
Concord, Australia
ML

Masa Lasica, MBBS, BMedSci, FRACP, FRCPA

Clinical Haematologist
St Vincent's Hospital Melbourne
Melbourne, Victoria, Australia
AA

Alejandro Arbelaez, MBBS, FRACP, FRCPA

Pindara Private Hospital
Benowa, Queensland, Australia
Stephan Stilgenbauer, MD

Professor of Medicine, Medical Director
Division of CLL, Internal Medicine III, Ulm University
Ulm, Baden-Wurttemberg, Germany
PB

Peter Browett, BMedSc, MB ChB, FRACP, FRCPA

Auckland City Hospital
Grafton, Auckland, New Zealand
SL

Sophie Leitch, MB, ChB, FRACP

Te Whatu Ora, Health New Zealand
Waitemata, Auckland, New Zealand
EG

Eva González-Barca, MD, PhD

Institut Català d’Oncologia Hospitalet, Universitat de Barcelona, IDIBELL
Barcelona, Catalonia, Spain
Mazyar Shadman, MD, MPH

Professor
Fred Hutchinson Cancer Center
Seattle, Washington, United States
JH

Jing-Zhou Hou, MD, PhD

University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
HE

Herbert Eradat, MD

David Geffen School of Medicine at UCLA
Los Angeles, California, United States
DW

David A. Westerman, MBBS, FRCPA, FRACP

Head of Haematopathology
Peter MacCallum Cancer Centre; University of Melbourne
Melbourne, Australia
YF

Yiqian Fang, PhD

BeOne Medicines Ltd
Shanghai, Shanghai, China (People's Republic)
JH

James Hilger, PhD

BeOne Medicines Ltd
San Carlos, California, United States
SP

Sheel Patel, PharmD

BeOne Medicines Ltd
San Carlos, California, United States
CC

Chan Y. Y. Cheah, MD

Haematologist
Sir Charles Gairdner Hospital; Medical School, University of Western Australia; Linear Clinical Research
Nedlands, Australia